Biosysen Limited has unveiled a non-underwritten rights issue to raise up to HK$40.56 million (net proceeds: HK$39.56 million). Shareholders will be offered one new share for every two held at HK$0.068 each— a 51.43% discount to the HK$0.140 closing price on 24 June 2026 (last trading day before announcement) and a 41.38% discount to the theoretical ex-rights price of HK$0.116.

A maximum of 596.53 million rights shares may be issued, expanding the share base by 50% to 1.79 billion. Trading in nil-paid rights runs from 6–13 August 2026, with acceptance and payment due by 18 August. Unsubscribed entitlements and any shares not taken up by overseas investors will be placed on a best-efforts basis by Tiger Faith Securities from 26 August to 2 September; unplaced shares will be cancelled, shrinking the final issue size accordingly. Results are slated for release on 7 September, with fully paid shares set to commence trading on 9 September.

Use of proceeds (assuming full take-up) is earmarked as follows: • HK$13.00 million (33.3%) for ongoing research and development across four proprietary healthcare and beauty projects, including staff costs and testing. • HK$8.00 million (20.5%) for sales and marketing of the healthcare and beauty business. • HK$6.00 million (15.4%) for renovation and upgrades of the Group’s hotel properties. • HK$12.00 million (30.8%) for general working capital, covering inventory, receivables, deposits and operating expenses.

The rights issue is not underwritten; if it is not fully subscribed, shareholders’ stakes will be diluted. Completion is conditional upon Stock Exchange approval, registration of prospectus documents and the Placing Agreement remaining in force.

Key dates include an ex-rights date of 24 July 2026 and a record date of 3 August 2026. The rights issue will proceed regardless of subscription level, and investors are advised to note that any rights not exercised will lapse without compensation.